Digital biomarkers and cognitive decline in mild cognitive impairment

The convergence of consumer-grade sensors and clinical neuroscience has reshaped how researchers approach early detection of neurodegenerative change. Where paper-and-pen batteries once defined cognitive assessment, continuous streams of behavioural and physiological data now complement episodic testing, offering a richer picture of how the brain operates in everyday life.

Mild cognitive impairment holds a central place in these conversations. It marks a transitional phase between typical ageing and dementia, where accurate prediction can shape years of decision-making. Digital biomarkers promise finer granularity than an annual recall of forgotten appointments, and the topic appears routinely at gatherings such as the INS mid-year meeting in Prague.

For clinicians in Australia, the appeal runs alongside well-known local pressures. Dementia is the leading cause of death among Australian women, and the Australian Institute of Health and Welfare estimates that more than 400,000 Australians live with the condition. The motivation to adopt predictive digital tools is immediate, particularly where specialist access is uneven.

This piece explores what digital biomarkers are, how they can forecast progression in mild cognitive impairment, and what Australian practitioners should weigh as the evidence matures.

Defining digital biomarkers in neuropsychology

A digital biomarker is a quantifiable signal collected through a digital device that reflects a biological state. In neuropsychology, signals often include gait patterns from accelerometers, keystroke dynamics logged by smartphones, voice features recorded during calls, and sleep architecture inferred from wrist sensors.

Traditional testing captures performance at a single moment, influenced by arousal and examiner familiarity. Digital biomarkers instead sample behaviour repeatedly under naturalistic conditions, surfacing trajectories a clinic visit rarely reveals.

Australian groups have contributed to validation. Teams at the University of Melbourne and Monash have explored smartphone-based micro-tests, while the Turner Institute for Brain and Mental Health has examined wearable-derived gait markers in older adults.

Passive sensing and subtle cognitive drift

Passive sensing is the unobtrusive collection of behavioural data without an active task. A watch recording step variability, a phone noting typing speed during messaging, or a voice assistant logging pause patterns during casual conversation generate signals relevant to cognitive health, forming a personal baseline against which deviation becomes meaningful over months.

In mild cognitive impairment, the earliest markers often appear in executive function and processing speed rather than memory. Digital biomarkers sensitive to these domains include typing latency, voice-onset hesitations, and reduced daily routine variability captured by smart-home sensors. Differences between stable MCI and converter-to-dementia groups often exceed episodic testing findings.

Distinguishing meaningful decline from normal variation is difficult. Australians who enjoy long daily walks along the coast show different step variability profiles than those whose routines are dominated by indoor activity, and algorithms must adjust for such cultural differences.

Cognitive testing beyond the clinic

Active cognitive micro-assessments delivered through apps offer a middle ground. Short gamified tasks measuring reaction time, spatial memory, and divided attention can be completed on a tablet on the kitchen bench in Brisbane or a phone handed to a grandparent in rural Western Australia, building a trajectory no single clinic visit can match.

Engagement depends on design. Australian clinicians have begun pairing such apps with stroke and dementia platforms to integrate cognitive monitoring into rehabilitation pathways, although reliability depends on cultural fit. Tools designed in northern hemisphere settings may translate poorly to Australian living arrangements, where multigenerational households and outdoor lifestyles shape how often devices are worn.

The Australian clinical landscape

Australia's health system combines universal coverage with a strong private memory clinic sector, giving developers varied terrain for deployment. Public clinics in Sydney, Melbourne, Adelaide, and Perth see hundreds of new MCI referrals each year, while the Australian Dementia Network works to standardise assessment across states.

Reimbursement remains a barrier. The Medicare Benefits Schedule does not yet include a specific item for continuous digital monitoring, slowing private uptake while hospital teams fare better by bundling the technology into broader neurology or geriatrics services.

Indigenous services add another layer. Programs supporting older Aboriginal and Torres Strait Islander adults in remote communities must balance the promise of digital monitoring with concerns about data sovereignty and consent. Co-designed approaches through Aboriginal Community Controlled Health Organisations are beginning to address these tensions.

Ethical and practical considerations

Continuous digital monitoring creates streams of intimate data. Cognitive decline predictions carry weighty implications for employment, insurance, and driving, particularly where licence renewal depends on medical assessment. Australian privacy law under the Australian Privacy Principles places strict duties on health data handling, though enforcement depends on local governance.

Informed consent introduces its own complexity. Patients in early MCI usually retain capacity, yet progression may erode that capacity over the life of any monitoring program. Dynamic consent models, where participants revisit their preferences, have gained traction in Australian trials.

There is also the question of who interprets the data. A clinician reviewing a six-month longitudinal profile needs training most postgraduate curricula provide only sparsely. The University of Sydney is now embedding digital phenotyping in its advanced subjects.

Pathways toward routine clinical use

Wider adoption will depend on prospective validation in diverse Australian cohorts, regulatory clarity, and reimbursement that recognises prevention rather than diagnosis alone. Trials underway through collaborations between the Florey Institute and hospital networks in Victoria are producing the longitudinal data needed for regulatory submission.

Education runs in parallel. Practitioners who reviewed continuing education sessions such as those summarised in INS 2018 workshop materials explored what these platforms require, and similar programmes are now offered by the Australasian Society for Cognitive Science.

For Australian patients and families, the prospect is quieter monitoring that respects daily life while offering earlier signals than episodic testing allows. The tools are imperfect and cultural fit requires constant care, but the trajectory points toward a practice where cognitive decline can be anticipated rather than documented after the fact.